mloh77 personal page - To The Moon

mloh77

mloh77

No personal profile

23Follow

4Followers

0Topic

0Badge

2022-06-24

$8VI Holdings Ltd(8VI.AU)$😰😭

2021-09-02

$8VIC(8VI.AU)$Why keep dropping?

2021-07-15

$8VIC(8VI.AU)$Think long-term.

2021-07-10

Yes, more than 99% making losses. ?

@Tom_Jerry:$Meta Materials Inc.(MMAT)$估計很多人跟我一樣都是負數，希望它能慢慢回升，給支持它的人信心。下週加油⛽。

2021-06-29

Go for it

2021-06-29

Good

Sorry, the original content has been removed

2021-06-29

$Regis Resources Ltd(RRL.AU)$Every method shows its undervalued, so why price keeps dropping?

2021-06-28

$Meta Materials Inc.(MMAT)$Drop till what value?

2021-06-28

$Meta Materials Inc.(MMAT)$Why couldnt i sell?

2021-06-28

$Torchlight Energy Resources Inc(MMAT)$My 200 shares will become 100 shares. Average cost of $5.38 will become $10.76.

2021-06-24

$Pro Medicus Ltd(PME.AU)$Who else is here because of Investopia?

2021-06-23

Slow and steady

2021-06-22

$Orphazyme A/S(ORPH)$How low will it go? I average down from $17 to $6…

2021-06-22

$Tiger Brokers(TIGR)$Keep the faith

2021-06-22

$Fisher & Paykel Healthcare Corp. Ltd.(FSPKF)$Anyone bought this because of Investopia?

2021-06-22

To buy or not to buy?

2021-06-22

$Docusign(DOCU)$patience

2021-06-21

Crypto drop

Sorry, the original content has been removed

2021-06-21

Noted

Orphazyme rose more than 6% in premarket trading

2021-06-19

$Orphazyme A/S(ORPH)$Patience

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":"3581752686297380","uuid":"3581752686297380","gmtCreate":1618658691258,"gmtModify":1623377470270,"name":"mloh77","pinyin":"mloh77","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/01590b23793ed123fade949ec8bb1c7e","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":4,"headSize":23,"tweetSize":38,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":3,"name":"书生虎","nameTw":"書生虎","represent":"努力向上","factor":"发布10条非转发主帖,其中5条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-3","templateUuid":"1026c425416b44e0aac28c11a0848493","name":" Tiger Idol","description":"Join the tiger community for 1500 days","bigImgUrl":"https://static.tigerbbs.com/8b40ae7da5bf081a1c84df14bf9e6367","smallImgUrl":"https://static.tigerbbs.com/f160eceddd7c284a8e1136557615cfad","grayImgUrl":"https://static.tigerbbs.com/11792805c468334a9b31c39f95a41c6a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.05.27","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"44212b71d0be4ec88898348dbe882e03-3","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"President Tiger","description":"The transaction amount of the securities account reaches $1,000,000","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","grayImgUrl":"https://static.tigerbbs.com/506a259a7b456f037592c3b23c779599","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"93.53%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"972123088c9646f7b6091ae0662215be-3","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Legendary Trader","description":"Total number of securities or futures transactions reached 300","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.29","exceedPercentage":"93.59%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":9041526941,"gmtCreate":1656077685784,"gmtModify":1676535763451,"author":{"id":"3581752686297380","authorId":"3581752686297380","name":"mloh77","avatar":"https://static.tigerbbs.com/01590b23793ed123fade949ec8bb1c7e","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581752686297380","idStr":"3581752686297380"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/8VI.AU\">$8VI Holdings Ltd(8VI.AU)$</a>😰😭","listText":"<a href=\"https://ttm.financial/S/8VI.AU\">$8VI Holdings Ltd(8VI.AU)$</a>😰😭","text":"$8VI Holdings Ltd(8VI.AU)$😰😭","images":[{"img":"https://community-static.tradeup.com/news/781826516bf8bcd0f956dc8972f52255","width":"1170","height":"2532"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9041526941","isVote":1,"tweetType":1,"viewCount":2298,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":812305702,"gmtCreate":1630550391706,"gmtModify":1676530337716,"author":{"id":"3581752686297380","authorId":"3581752686297380","name":"mloh77","avatar":"https://static.tigerbbs.com/01590b23793ed123fade949ec8bb1c7e","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581752686297380","idStr":"3581752686297380"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/8VI.AU\">$8VIC(8VI.AU)$</a>Why keep dropping?","listText":"<a href=\"https://laohu8.com/S/8VI.AU\">$8VIC(8VI.AU)$</a>Why keep dropping?","text":"$8VIC(8VI.AU)$Why keep dropping?","images":[{"img":"https://static.tigerbbs.com/aa5451c54123e50683eb394180ce6caa","width":"828","height":"1792"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/812305702","isVote":1,"tweetType":1,"viewCount":3009,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":144489240,"gmtCreate":1626310111780,"gmtModify":1703757542580,"author":{"id":"3581752686297380","authorId":"3581752686297380","name":"mloh77","avatar":"https://static.tigerbbs.com/01590b23793ed123fade949ec8bb1c7e","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581752686297380","idStr":"3581752686297380"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/8VI.AU\">$8VIC(8VI.AU)$</a>Think long-term.","listText":"<a href=\"https://laohu8.com/S/8VI.AU\">$8VIC(8VI.AU)$</a>Think long-term.","text":"$8VIC(8VI.AU)$Think long-term.","images":[{"img":"https://static.tigerbbs.com/a3f5c4ee61f02feda0f31a0adcd6c7ca","width":"828","height":"1434"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/144489240","isVote":1,"tweetType":1,"viewCount":3139,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3562206499105387","authorId":"3562206499105387","name":"CY_Ng","avatar":"https://static.tigerbbs.com/eba016392472f02387b5ae5505dbc524","crmLevel":12,"crmLevelSwitch":1,"authorIdStr":"3562206499105387","idStr":"3562206499105387"},"content":"the hype is finish. company need to deliver more exciting result to push the share price further up. latest report is not that exciting.","text":"the hype is finish. company need to deliver more exciting result to push the share price further up. latest report is not that exciting.","html":"the hype is finish. company need to deliver more exciting result to push the share price further up. latest report is not that exciting."}],"imageCount":1,"langContent":"EN","totalScore":0},{"id":141575362,"gmtCreate":1625883146456,"gmtModify":1703750373331,"author":{"id":"3581752686297380","authorId":"3581752686297380","name":"mloh77","avatar":"https://static.tigerbbs.com/01590b23793ed123fade949ec8bb1c7e","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581752686297380","idStr":"3581752686297380"},"themes":[],"htmlText":"Yes, more than 99% making losses. ?","listText":"Yes, more than 99% making losses. ?","text":"Yes, more than 99% making losses. ?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/141575362","repostId":"141259623","repostType":1,"repost":{"id":141259623,"gmtCreate":1625876519462,"gmtModify":1703750190921,"author":{"id":"3571209718541642","authorId":"3571209718541642","name":"Tom_Jerry","avatar":"https://static.tigerbbs.com/5ce158ae76ab06ae07b990f57e8ced26","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3571209718541642","idStr":"3571209718541642"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/MMAT\">$Meta Materials Inc.(MMAT)$</a>估計很多人跟我一樣都是負數，希望它能慢慢回升，給支持它的人信心。下週加油⛽。","listText":"<a href=\"https://laohu8.com/S/MMAT\">$Meta Materials Inc.(MMAT)$</a>估計很多人跟我一樣都是負數，希望它能慢慢回升，給支持它的人信心。下週加油⛽。","text":"$Meta Materials Inc.(MMAT)$估計很多人跟我一樣都是負數，希望它能慢慢回升，給支持它的人信心。下週加油⛽。","images":[{"img":"https://static.tigerbbs.com/41f0634abcad01d37e0cedf08f37544f","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/141259623","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":1746,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":159502528,"gmtCreate":1624973378164,"gmtModify":1703849137568,"author":{"id":"3581752686297380","authorId":"3581752686297380","name":"mloh77","avatar":"https://static.tigerbbs.com/01590b23793ed123fade949ec8bb1c7e","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581752686297380","idStr":"3581752686297380"},"themes":[],"htmlText":"Go for it","listText":"Go for it","text":"Go for it","images":[{"img":"https://static.tigerbbs.com/888b7250f82b7098d9fd7b887179688d","width":"750","height":"2216"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/159502528","isVote":1,"tweetType":1,"viewCount":1735,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":159506962,"gmtCreate":1624973270756,"gmtModify":1703849135786,"author":{"id":"3581752686297380","authorId":"3581752686297380","name":"mloh77","avatar":"https://static.tigerbbs.com/01590b23793ed123fade949ec8bb1c7e","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581752686297380","idStr":"3581752686297380"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/159506962","repostId":"1104222469","repostType":2,"isVote":1,"tweetType":1,"viewCount":1923,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":159136184,"gmtCreate":1624947030748,"gmtModify":1703848599718,"author":{"id":"3581752686297380","authorId":"3581752686297380","name":"mloh77","avatar":"https://static.tigerbbs.com/01590b23793ed123fade949ec8bb1c7e","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581752686297380","idStr":"3581752686297380"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/RRL.AU\">$Regis Resources Ltd(RRL.AU)$</a>Every method shows its undervalued, so why&nbsp;price keeps dropping?","listText":"<a href=\"https://laohu8.com/S/RRL.AU\">$Regis Resources Ltd(RRL.AU)$</a>Every method shows its undervalued, so why&nbsp;price keeps dropping?","text":"$Regis Resources Ltd(RRL.AU)$Every method shows its undervalued, so why price keeps dropping?","images":[{"img":"https://static.tigerbbs.com/f59c64927d47ce5bbdea971b87b4de3d","width":"828","height":"1792"},{"img":"https://static.tigerbbs.com/3d4bc6dcded30256a44196b8500600c8","width":"828","height":"1792"},{"img":"https://static.tigerbbs.com/7140f78193b3385d27328f29726c6aea","width":"828","height":"1792"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/159136184","isVote":1,"tweetType":1,"viewCount":1798,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":3,"langContent":"EN","totalScore":0},{"id":150820489,"gmtCreate":1624893360541,"gmtModify":1703847370955,"author":{"id":"3581752686297380","authorId":"3581752686297380","name":"mloh77","avatar":"https://static.tigerbbs.com/01590b23793ed123fade949ec8bb1c7e","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581752686297380","idStr":"3581752686297380"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/MMAT\">$Meta Materials Inc.(MMAT)$</a>Drop till what value?","listText":"<a href=\"https://laohu8.com/S/MMAT\">$Meta Materials Inc.(MMAT)$</a>Drop till what value?","text":"$Meta Materials Inc.(MMAT)$Drop till what value?","images":[{"img":"https://static.tigerbbs.com/7501f655659eda862070fa5820ada76b","width":"828","height":"1792"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/150820489","isVote":1,"tweetType":1,"viewCount":2385,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":150062098,"gmtCreate":1624876321614,"gmtModify":1703846787061,"author":{"id":"3581752686297380","authorId":"3581752686297380","name":"mloh77","avatar":"https://static.tigerbbs.com/01590b23793ed123fade949ec8bb1c7e","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581752686297380","idStr":"3581752686297380"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/MMAT\">$Meta Materials Inc.(MMAT)$</a>Why couldnt i sell?","listText":"<a href=\"https://laohu8.com/S/MMAT\">$Meta Materials Inc.(MMAT)$</a>Why couldnt i sell?","text":"$Meta Materials Inc.(MMAT)$Why couldnt i sell?","images":[{"img":"https://static.tigerbbs.com/9df6ebab45c76fec31572ae685a1cc69","width":"828","height":"1792"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":4,"repostSize":0,"link":"https://ttm.financial/post/150062098","isVote":1,"tweetType":1,"viewCount":4845,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":127466900,"gmtCreate":1624864391600,"gmtModify":1703846498472,"author":{"id":"3581752686297380","authorId":"3581752686297380","name":"mloh77","avatar":"https://static.tigerbbs.com/01590b23793ed123fade949ec8bb1c7e","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581752686297380","idStr":"3581752686297380"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/MMAT\">$Torchlight Energy Resources Inc(MMAT)$</a>My 200 shares will become 100 shares. Average cost of $5.38 will become $10.76.","listText":"<a href=\"https://laohu8.com/S/MMAT\">$Torchlight Energy Resources Inc(MMAT)$</a>My 200 shares will become 100 shares. Average cost of $5.38 will become $10.76.","text":"$Torchlight Energy Resources Inc(MMAT)$My 200 shares will become 100 shares. Average cost of $5.38 will become $10.76.","images":[{"img":"https://static.tigerbbs.com/bad92c5b105da0f6c28f4ceddb2cced6","width":"828","height":"1792"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/127466900","isVote":1,"tweetType":1,"viewCount":2603,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":2,"langContent":"EN","totalScore":0},{"id":128093601,"gmtCreate":1624494631003,"gmtModify":1703838213098,"author":{"id":"3581752686297380","authorId":"3581752686297380","name":"mloh77","avatar":"https://static.tigerbbs.com/01590b23793ed123fade949ec8bb1c7e","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581752686297380","idStr":"3581752686297380"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/PME.AU\">$Pro Medicus Ltd(PME.AU)$</a>Who else is here because of Investopia?","listText":"<a href=\"https://laohu8.com/S/PME.AU\">$Pro Medicus Ltd(PME.AU)$</a>Who else is here because of Investopia?","text":"$Pro Medicus Ltd(PME.AU)$Who else is here because of Investopia?","images":[{"img":"https://static.tigerbbs.com/a7437c8a39c054aa2a45c36063315d19","width":"828","height":"1434"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/128093601","isVote":1,"tweetType":1,"viewCount":815,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":123301731,"gmtCreate":1624408016023,"gmtModify":1703835665278,"author":{"id":"3581752686297380","authorId":"3581752686297380","name":"mloh77","avatar":"https://static.tigerbbs.com/01590b23793ed123fade949ec8bb1c7e","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581752686297380","idStr":"3581752686297380"},"themes":[],"htmlText":"Slow and steady","listText":"Slow and steady","text":"Slow and steady","images":[{"img":"https://static.tigerbbs.com/dd724599fae65e2928972a9d86670445","width":"750","height":"1743"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/123301731","isVote":1,"tweetType":1,"viewCount":839,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":129663474,"gmtCreate":1624371212298,"gmtModify":1703834745572,"author":{"id":"3581752686297380","authorId":"3581752686297380","name":"mloh77","avatar":"https://static.tigerbbs.com/01590b23793ed123fade949ec8bb1c7e","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581752686297380","idStr":"3581752686297380"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/ORPH\">$Orphazyme A/S(ORPH)$</a>How low will it go? I average down from $17 to $6…","listText":"<a href=\"https://laohu8.com/S/ORPH\">$Orphazyme A/S(ORPH)$</a>How low will it go? I average down from $17 to $6…","text":"$Orphazyme A/S(ORPH)$How low will it go? I average down from $17 to $6…","images":[{"img":"https://static.tigerbbs.com/ab023e422668b123bc4abb809f4f8ae4","width":"828","height":"1434"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":4,"repostSize":0,"link":"https://ttm.financial/post/129663474","isVote":1,"tweetType":1,"viewCount":2073,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":129128525,"gmtCreate":1624366007367,"gmtModify":1703834476370,"author":{"id":"3581752686297380","authorId":"3581752686297380","name":"mloh77","avatar":"https://static.tigerbbs.com/01590b23793ed123fade949ec8bb1c7e","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581752686297380","idStr":"3581752686297380"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>Keep the faith","listText":"<a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>Keep the faith","text":"$Tiger Brokers(TIGR)$Keep the faith","images":[{"img":"https://static.tigerbbs.com/506220a9dd82cf8d5c9db2443fecc06b","width":"828","height":"1434"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":1,"link":"https://ttm.financial/post/129128525","isVote":1,"tweetType":1,"viewCount":1158,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":129129436,"gmtCreate":1624365875725,"gmtModify":1703834472311,"author":{"id":"3581752686297380","authorId":"3581752686297380","name":"mloh77","avatar":"https://static.tigerbbs.com/01590b23793ed123fade949ec8bb1c7e","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581752686297380","idStr":"3581752686297380"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/FSPKF\">$Fisher &amp; Paykel Healthcare Corp. Ltd.(FSPKF)$</a>Anyone&nbsp;bought this because of Investopia?","listText":"<a href=\"https://laohu8.com/S/FSPKF\">$Fisher &amp; Paykel Healthcare Corp. Ltd.(FSPKF)$</a>Anyone&nbsp;bought this because of Investopia?","text":"$Fisher & Paykel Healthcare Corp. Ltd.(FSPKF)$Anyone bought this because of Investopia?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/129129436","isVote":1,"tweetType":1,"viewCount":835,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":129181361,"gmtCreate":1624365103753,"gmtModify":1703834446987,"author":{"id":"3581752686297380","authorId":"3581752686297380","name":"mloh77","avatar":"https://static.tigerbbs.com/01590b23793ed123fade949ec8bb1c7e","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581752686297380","idStr":"3581752686297380"},"themes":[],"htmlText":"To buy or not to buy?","listText":"To buy or not to buy?","text":"To buy or not to buy?","images":[{"img":"https://static.tigerbbs.com/064c9e4cea9eefb35e2f8e8ce664260a","width":"750","height":"2216"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/129181361","isVote":1,"tweetType":1,"viewCount":567,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":129189815,"gmtCreate":1624365032137,"gmtModify":1703834444556,"author":{"id":"3581752686297380","authorId":"3581752686297380","name":"mloh77","avatar":"https://static.tigerbbs.com/01590b23793ed123fade949ec8bb1c7e","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581752686297380","idStr":"3581752686297380"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/DOCU\">$Docusign(DOCU)$</a>patience","listText":"<a href=\"https://laohu8.com/S/DOCU\">$Docusign(DOCU)$</a>patience","text":"$Docusign(DOCU)$patience","images":[{"img":"https://static.tigerbbs.com/54995e5c1554ec254eaa32ca807c5196","width":"828","height":"1434"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/129189815","isVote":1,"tweetType":1,"viewCount":666,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":167269139,"gmtCreate":1624271257921,"gmtModify":1703832065195,"author":{"id":"3581752686297380","authorId":"3581752686297380","name":"mloh77","avatar":"https://static.tigerbbs.com/01590b23793ed123fade949ec8bb1c7e","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581752686297380","idStr":"3581752686297380"},"themes":[],"htmlText":"Crypto drop","listText":"Crypto drop","text":"Crypto drop","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/167269139","repostId":"1147979715","repostType":4,"isVote":1,"tweetType":1,"viewCount":651,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":167260927,"gmtCreate":1624271213869,"gmtModify":1703832068046,"author":{"id":"3581752686297380","authorId":"3581752686297380","name":"mloh77","avatar":"https://static.tigerbbs.com/01590b23793ed123fade949ec8bb1c7e","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581752686297380","idStr":"3581752686297380"},"themes":[],"htmlText":"Noted","listText":"Noted","text":"Noted","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/167260927","repostId":"1184501396","repostType":4,"repost":{"id":"1184501396","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1624267024,"share":"https://ttm.financial/m/news/1184501396?lang=&edition=fundamental","pubTime":"2021-06-21 17:17","market":"us","language":"en","title":"Orphazyme rose more than 6% in premarket trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1184501396","media":"Tiger Newspress","summary":"(June 21) Orphazyme rose more than 6% in premarket trading. \n\nWhat happened\nShares of Orphazyme, a c","content":"<p>(June 21)&nbsp;Orphazyme rose more than 6% in premarket trading.&nbsp;</p>\n<p><img src=\"https://static.tigerbbs.com/a1e2eb27cc68ce74ddd21a64a64634cf\" tg-width=\"719\" tg-height=\"495\" referrerpolicy=\"no-referrer\"></p>\n<p><b>What happened</b></p>\n<p>Shares of&nbsp;<b>Orphazyme</b>, a clinical-stage biopharmaceutical company, got hammered after the Food and Drug Administration (FDA) refused to approve an application for the company's lead candidate. Investors are now uncertain when the biotech could have an approved product to sell, and pushed the stock 44.4% lower as of 12:12 p.m. EDT on last&nbsp;Friday.</p>\n<p><b>So what</b></p>\n<p>The FDA began reviewing an application for Orphazyme's lead candidate arimoclomol last September as a potential treatment for a rare but life-threatening disease called Neimann-Pick Disease Type-C (NPC). Earlier this month, shares of Orphazymeshot upmore than 200% in anticipation of a green light that never came.</p>\n<p>Instead of an approval decision for arimoclomol, the agency asked for more information in the form of a complete response letter (CRL). That came as a shock to heaps of investors who were new to the complex world of drug development and were expecting a massiveshort squeeze.</p>\n<p>Many institutional investors were betting against Orphazyme because its lead candidate failed to achieve the primary endpoint in the pivotal study underpinning the application. Arimoclomol also failed to improve patients' scores on a secondary endpoint specifically requested by the FDA.</p>\n<p><b>Now what</b></p>\n<p>According to Orphazyme, the company needs to further substantiate the validity of the primary endpoint that arimoclomol almost achieved. To satisfy the FDA, the company will most likely have to run a new pivotal study.</p>\n<p>Some shareholders remain hopeful that the European Medicines Agency will be less strict than the FDA. While the FDA's European colleague has been more lenient regarding treatments for rare diseases in the past, arimoclomol probably isn't moving forward until it produces some convincing clinical-trial results.</p>\n<p>Despite lacking a clear path forward, the Denmark-headquartered company still boasts a fairly large market cap in excess of $500 million at recent prices. Irrational expectations could keep it elevated, but this is way too high for anyclinical-stage biotechin Orphazyme's position.</p>\n<p></p>\n<p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Orphazyme rose more than 6% in premarket trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOrphazyme rose more than 6% in premarket trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-06-21 17:17</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(June 21)&nbsp;Orphazyme rose more than 6% in premarket trading.&nbsp;</p>\n<p><img src=\"https://static.tigerbbs.com/a1e2eb27cc68ce74ddd21a64a64634cf\" tg-width=\"719\" tg-height=\"495\" referrerpolicy=\"no-referrer\"></p>\n<p><b>What happened</b></p>\n<p>Shares of&nbsp;<b>Orphazyme</b>, a clinical-stage biopharmaceutical company, got hammered after the Food and Drug Administration (FDA) refused to approve an application for the company's lead candidate. Investors are now uncertain when the biotech could have an approved product to sell, and pushed the stock 44.4% lower as of 12:12 p.m. EDT on last&nbsp;Friday.</p>\n<p><b>So what</b></p>\n<p>The FDA began reviewing an application for Orphazyme's lead candidate arimoclomol last September as a potential treatment for a rare but life-threatening disease called Neimann-Pick Disease Type-C (NPC). Earlier this month, shares of Orphazymeshot upmore than 200% in anticipation of a green light that never came.</p>\n<p>Instead of an approval decision for arimoclomol, the agency asked for more information in the form of a complete response letter (CRL). That came as a shock to heaps of investors who were new to the complex world of drug development and were expecting a massiveshort squeeze.</p>\n<p>Many institutional investors were betting against Orphazyme because its lead candidate failed to achieve the primary endpoint in the pivotal study underpinning the application. Arimoclomol also failed to improve patients' scores on a secondary endpoint specifically requested by the FDA.</p>\n<p><b>Now what</b></p>\n<p>According to Orphazyme, the company needs to further substantiate the validity of the primary endpoint that arimoclomol almost achieved. To satisfy the FDA, the company will most likely have to run a new pivotal study.</p>\n<p>Some shareholders remain hopeful that the European Medicines Agency will be less strict than the FDA. While the FDA's European colleague has been more lenient regarding treatments for rare diseases in the past, arimoclomol probably isn't moving forward until it produces some convincing clinical-trial results.</p>\n<p>Despite lacking a clear path forward, the Denmark-headquartered company still boasts a fairly large market cap in excess of $500 million at recent prices. Irrational expectations could keep it elevated, but this is way too high for anyclinical-stage biotechin Orphazyme's position.</p>\n<p></p>\n<p></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1184501396","content_text":"(June 21) Orphazyme rose more than 6% in premarket trading. \n\nWhat happened\nShares of Orphazyme, a clinical-stage biopharmaceutical company, got hammered after the Food and Drug Administration (FDA) refused to approve an application for the company's lead candidate. Investors are now uncertain when the biotech could have an approved product to sell, and pushed the stock 44.4% lower as of 12:12 p.m. EDT on last Friday.\nSo what\nThe FDA began reviewing an application for Orphazyme's lead candidate arimoclomol last September as a potential treatment for a rare but life-threatening disease called Neimann-Pick Disease Type-C (NPC). Earlier this month, shares of Orphazymeshot upmore than 200% in anticipation of a green light that never came.\nInstead of an approval decision for arimoclomol, the agency asked for more information in the form of a complete response letter (CRL). That came as a shock to heaps of investors who were new to the complex world of drug development and were expecting a massiveshort squeeze.\nMany institutional investors were betting against Orphazyme because its lead candidate failed to achieve the primary endpoint in the pivotal study underpinning the application. Arimoclomol also failed to improve patients' scores on a secondary endpoint specifically requested by the FDA.\nNow what\nAccording to Orphazyme, the company needs to further substantiate the validity of the primary endpoint that arimoclomol almost achieved. To satisfy the FDA, the company will most likely have to run a new pivotal study.\nSome shareholders remain hopeful that the European Medicines Agency will be less strict than the FDA. While the FDA's European colleague has been more lenient regarding treatments for rare diseases in the past, arimoclomol probably isn't moving forward until it produces some convincing clinical-trial results.\nDespite lacking a clear path forward, the Denmark-headquartered company still boasts a fairly large market cap in excess of $500 million at recent prices. Irrational expectations could keep it elevated, but this is way too high for anyclinical-stage biotechin Orphazyme's position.","news_type":1,"symbols_score_info":{"ORPH":0.9}},"isVote":1,"tweetType":1,"viewCount":559,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":162128293,"gmtCreate":1624045699512,"gmtModify":1703827522762,"author":{"id":"3581752686297380","authorId":"3581752686297380","name":"mloh77","avatar":"https://static.tigerbbs.com/01590b23793ed123fade949ec8bb1c7e","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581752686297380","idStr":"3581752686297380"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/ORPH\">$Orphazyme A/S(ORPH)$</a>Patience","listText":"<a href=\"https://laohu8.com/S/ORPH\">$Orphazyme A/S(ORPH)$</a>Patience","text":"$Orphazyme A/S(ORPH)$Patience","images":[{"img":"https://static.tigerbbs.com/82df7e0afaf3a94bb43b6a376ce627b9","width":"828","height":"1434"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":4,"repostSize":0,"link":"https://ttm.financial/post/162128293","isVote":1,"tweetType":1,"viewCount":2025,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0}],"hots":[{"id":162128293,"gmtCreate":1624045699512,"gmtModify":1703827522762,"author":{"id":"3581752686297380","authorId":"3581752686297380","name":"mloh77","avatar":"https://static.tigerbbs.com/01590b23793ed123fade949ec8bb1c7e","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581752686297380","authorIdStr":"3581752686297380"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/ORPH\">$Orphazyme A/S(ORPH)$</a>Patience","listText":"<a href=\"https://laohu8.com/S/ORPH\">$Orphazyme A/S(ORPH)$</a>Patience","text":"$Orphazyme A/S(ORPH)$Patience","images":[{"img":"https://static.tigerbbs.com/82df7e0afaf3a94bb43b6a376ce627b9","width":"828","height":"1434"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":4,"repostSize":0,"link":"https://ttm.financial/post/162128293","isVote":1,"tweetType":1,"viewCount":2025,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":129663474,"gmtCreate":1624371212298,"gmtModify":1703834745572,"author":{"id":"3581752686297380","authorId":"3581752686297380","name":"mloh77","avatar":"https://static.tigerbbs.com/01590b23793ed123fade949ec8bb1c7e","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581752686297380","authorIdStr":"3581752686297380"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/ORPH\">$Orphazyme A/S(ORPH)$</a>How low will it go? I average down from $17 to $6…","listText":"<a href=\"https://laohu8.com/S/ORPH\">$Orphazyme A/S(ORPH)$</a>How low will it go? I average down from $17 to $6…","text":"$Orphazyme A/S(ORPH)$How low will it go? I average down from $17 to $6…","images":[{"img":"https://static.tigerbbs.com/ab023e422668b123bc4abb809f4f8ae4","width":"828","height":"1434"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":4,"repostSize":0,"link":"https://ttm.financial/post/129663474","isVote":1,"tweetType":1,"viewCount":2073,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":181871509,"gmtCreate":1623387131101,"gmtModify":1704202275620,"author":{"id":"3581752686297380","authorId":"3581752686297380","name":"mloh77","avatar":"https://static.tigerbbs.com/01590b23793ed123fade949ec8bb1c7e","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581752686297380","authorIdStr":"3581752686297380"},"themes":[],"htmlText":"Record","listText":"Record","text":"Record","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/181871509","repostId":"1184070773","repostType":4,"isVote":1,"tweetType":1,"viewCount":614,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3571630433284403","authorId":"3571630433284403","name":"cHao7","avatar":"https://static.tigerbbs.com/3800b5d66328f3184368a219227b02a3","crmLevel":11,"crmLevelSwitch":0,"idStr":"3571630433284403","authorIdStr":"3571630433284403"},"content":"comment plz","text":"comment plz","html":"comment plz"}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":187912378,"gmtCreate":1623734386494,"gmtModify":1704209941760,"author":{"id":"3581752686297380","authorId":"3581752686297380","name":"mloh77","avatar":"https://static.tigerbbs.com/01590b23793ed123fade949ec8bb1c7e","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581752686297380","authorIdStr":"3581752686297380"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/8VI.AU\">$8VIC(8VI.AU)$</a>Yayness! reach 5 dollars ?","listText":"<a href=\"https://laohu8.com/S/8VI.AU\">$8VIC(8VI.AU)$</a>Yayness! reach 5 dollars ?","text":"$8VIC(8VI.AU)$Yayness! reach 5 dollars ?","images":[{"img":"https://static.tigerbbs.com/9d9f6b5d60ae5a5d622c2ba25788d5cf","width":"828","height":"1792"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/187912378","isVote":1,"tweetType":1,"viewCount":571,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3577855760701774","authorId":"3577855760701774","name":"fredke","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":13,"crmLevelSwitch":1,"idStr":"3577855760701774","authorIdStr":"3577855760701774"},"content":"coming to $6 today!","text":"coming to $6 today!","html":"coming to $6 today!"}],"imageCount":1,"langContent":"EN","totalScore":0},{"id":150062098,"gmtCreate":1624876321614,"gmtModify":1703846787061,"author":{"id":"3581752686297380","authorId":"3581752686297380","name":"mloh77","avatar":"https://static.tigerbbs.com/01590b23793ed123fade949ec8bb1c7e","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581752686297380","authorIdStr":"3581752686297380"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/MMAT\">$Meta Materials Inc.(MMAT)$</a>Why couldnt i sell?","listText":"<a href=\"https://laohu8.com/S/MMAT\">$Meta Materials Inc.(MMAT)$</a>Why couldnt i sell?","text":"$Meta Materials Inc.(MMAT)$Why couldnt i sell?","images":[{"img":"https://static.tigerbbs.com/9df6ebab45c76fec31572ae685a1cc69","width":"828","height":"1792"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":4,"repostSize":0,"link":"https://ttm.financial/post/150062098","isVote":1,"tweetType":1,"viewCount":4845,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":169005679,"gmtCreate":1623808155991,"gmtModify":1703820068752,"author":{"id":"3581752686297380","authorId":"3581752686297380","name":"mloh77","avatar":"https://static.tigerbbs.com/01590b23793ed123fade949ec8bb1c7e","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581752686297380","authorIdStr":"3581752686297380"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/8VI.AU\">$8VIC(8VI.AU)$</a>Rocket","listText":"<a href=\"https://laohu8.com/S/8VI.AU\">$8VIC(8VI.AU)$</a>Rocket","text":"$8VIC(8VI.AU)$Rocket","images":[{"img":"https://static.tigerbbs.com/34fa198ad09eee4f47226c9358d8bc75","width":"828","height":"1434"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/169005679","isVote":1,"tweetType":1,"viewCount":805,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":129128525,"gmtCreate":1624366007367,"gmtModify":1703834476370,"author":{"id":"3581752686297380","authorId":"3581752686297380","name":"mloh77","avatar":"https://static.tigerbbs.com/01590b23793ed123fade949ec8bb1c7e","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581752686297380","authorIdStr":"3581752686297380"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>Keep the faith","listText":"<a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>Keep the faith","text":"$Tiger Brokers(TIGR)$Keep the faith","images":[{"img":"https://static.tigerbbs.com/506220a9dd82cf8d5c9db2443fecc06b","width":"828","height":"1434"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":1,"link":"https://ttm.financial/post/129128525","isVote":1,"tweetType":1,"viewCount":1158,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":184497541,"gmtCreate":1623720968083,"gmtModify":1704209500396,"author":{"id":"3581752686297380","authorId":"3581752686297380","name":"mloh77","avatar":"https://static.tigerbbs.com/01590b23793ed123fade949ec8bb1c7e","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581752686297380","authorIdStr":"3581752686297380"},"themes":[],"htmlText":"Accumulate","listText":"Accumulate","text":"Accumulate","images":[{"img":"https://static.tigerbbs.com/1de9a2958afe92e5c342e5f99c2bbd8f","width":"750","height":"1743"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/184497541","isVote":1,"tweetType":1,"viewCount":692,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3581467266860645","authorId":"3581467266860645","name":"Newbiecub","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"idStr":"3581467266860645","authorIdStr":"3581467266860645"},"content":"Is there an intRinsic value chart for 8ih in VI App? How u find the app so far?","text":"Is there an intRinsic value chart for 8ih in VI App? How u find the app so far?","html":"Is there an intRinsic value chart for 8ih in VI App? How u find the app so far?"}],"imageCount":1,"langContent":"EN","totalScore":0},{"id":144489240,"gmtCreate":1626310111780,"gmtModify":1703757542580,"author":{"id":"3581752686297380","authorId":"3581752686297380","name":"mloh77","avatar":"https://static.tigerbbs.com/01590b23793ed123fade949ec8bb1c7e","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581752686297380","authorIdStr":"3581752686297380"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/8VI.AU\">$8VIC(8VI.AU)$</a>Think long-term.","listText":"<a href=\"https://laohu8.com/S/8VI.AU\">$8VIC(8VI.AU)$</a>Think long-term.","text":"$8VIC(8VI.AU)$Think long-term.","images":[{"img":"https://static.tigerbbs.com/a3f5c4ee61f02feda0f31a0adcd6c7ca","width":"828","height":"1434"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/144489240","isVote":1,"tweetType":1,"viewCount":3139,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3562206499105387","authorId":"3562206499105387","name":"CY_Ng","avatar":"https://static.tigerbbs.com/eba016392472f02387b5ae5505dbc524","crmLevel":12,"crmLevelSwitch":1,"idStr":"3562206499105387","authorIdStr":"3562206499105387"},"content":"the hype is finish. company need to deliver more exciting result to push the share price further up. latest report is not that exciting.","text":"the hype is finish. company need to deliver more exciting result to push the share price further up. latest report is not that exciting.","html":"the hype is finish. company need to deliver more exciting result to push the share price further up. latest report is not that exciting."}],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9041526941,"gmtCreate":1656077685784,"gmtModify":1676535763451,"author":{"id":"3581752686297380","authorId":"3581752686297380","name":"mloh77","avatar":"https://static.tigerbbs.com/01590b23793ed123fade949ec8bb1c7e","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581752686297380","authorIdStr":"3581752686297380"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/8VI.AU\">$8VI Holdings Ltd(8VI.AU)$</a>😰😭","listText":"<a href=\"https://ttm.financial/S/8VI.AU\">$8VI Holdings Ltd(8VI.AU)$</a>😰😭","text":"$8VI Holdings Ltd(8VI.AU)$😰😭","images":[{"img":"https://community-static.tradeup.com/news/781826516bf8bcd0f956dc8972f52255","width":"1170","height":"2532"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9041526941","isVote":1,"tweetType":1,"viewCount":2298,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":161427296,"gmtCreate":1623938774215,"gmtModify":1703824041815,"author":{"id":"3581752686297380","authorId":"3581752686297380","name":"mloh77","avatar":"https://static.tigerbbs.com/01590b23793ed123fade949ec8bb1c7e","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581752686297380","authorIdStr":"3581752686297380"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/ORPH\">$Orphazyme A/S(ORPH)$</a>stay cool","listText":"<a href=\"https://laohu8.com/S/ORPH\">$Orphazyme A/S(ORPH)$</a>stay cool","text":"$Orphazyme A/S(ORPH)$stay cool","images":[{"img":"https://static.tigerbbs.com/288ca559b16ab880152e95b6ee86f160","width":"828","height":"1434"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/161427296","isVote":1,"tweetType":1,"viewCount":502,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":186861256,"gmtCreate":1623485206975,"gmtModify":1704204935935,"author":{"id":"3581752686297380","authorId":"3581752686297380","name":"mloh77","avatar":"https://static.tigerbbs.com/01590b23793ed123fade949ec8bb1c7e","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581752686297380","authorIdStr":"3581752686297380"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/ORPH\">$Orphazyme A/S(ORPH)$</a>??","listText":"<a href=\"https://laohu8.com/S/ORPH\">$Orphazyme A/S(ORPH)$</a>??","text":"$Orphazyme A/S(ORPH)$??","images":[{"img":"https://static.tigerbbs.com/486a0e1bb80cd970271e4781e5901a16","width":"828","height":"1434"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/186861256","isVote":1,"tweetType":1,"viewCount":849,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":812305702,"gmtCreate":1630550391706,"gmtModify":1676530337716,"author":{"id":"3581752686297380","authorId":"3581752686297380","name":"mloh77","avatar":"https://static.tigerbbs.com/01590b23793ed123fade949ec8bb1c7e","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581752686297380","authorIdStr":"3581752686297380"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/8VI.AU\">$8VIC(8VI.AU)$</a>Why keep dropping?","listText":"<a href=\"https://laohu8.com/S/8VI.AU\">$8VIC(8VI.AU)$</a>Why keep dropping?","text":"$8VIC(8VI.AU)$Why keep dropping?","images":[{"img":"https://static.tigerbbs.com/aa5451c54123e50683eb394180ce6caa","width":"828","height":"1792"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/812305702","isVote":1,"tweetType":1,"viewCount":3009,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":150820489,"gmtCreate":1624893360541,"gmtModify":1703847370955,"author":{"id":"3581752686297380","authorId":"3581752686297380","name":"mloh77","avatar":"https://static.tigerbbs.com/01590b23793ed123fade949ec8bb1c7e","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581752686297380","authorIdStr":"3581752686297380"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/MMAT\">$Meta Materials Inc.(MMAT)$</a>Drop till what value?","listText":"<a href=\"https://laohu8.com/S/MMAT\">$Meta Materials Inc.(MMAT)$</a>Drop till what value?","text":"$Meta Materials Inc.(MMAT)$Drop till what value?","images":[{"img":"https://static.tigerbbs.com/7501f655659eda862070fa5820ada76b","width":"828","height":"1792"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/150820489","isVote":1,"tweetType":1,"viewCount":2385,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":127466900,"gmtCreate":1624864391600,"gmtModify":1703846498472,"author":{"id":"3581752686297380","authorId":"3581752686297380","name":"mloh77","avatar":"https://static.tigerbbs.com/01590b23793ed123fade949ec8bb1c7e","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581752686297380","authorIdStr":"3581752686297380"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/MMAT\">$Torchlight Energy Resources Inc(MMAT)$</a>My 200 shares will become 100 shares. Average cost of $5.38 will become $10.76.","listText":"<a href=\"https://laohu8.com/S/MMAT\">$Torchlight Energy Resources Inc(MMAT)$</a>My 200 shares will become 100 shares. Average cost of $5.38 will become $10.76.","text":"$Torchlight Energy Resources Inc(MMAT)$My 200 shares will become 100 shares. Average cost of $5.38 will become $10.76.","images":[{"img":"https://static.tigerbbs.com/bad92c5b105da0f6c28f4ceddb2cced6","width":"828","height":"1792"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/127466900","isVote":1,"tweetType":1,"viewCount":2603,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":2,"langContent":"EN","totalScore":0},{"id":129189815,"gmtCreate":1624365032137,"gmtModify":1703834444556,"author":{"id":"3581752686297380","authorId":"3581752686297380","name":"mloh77","avatar":"https://static.tigerbbs.com/01590b23793ed123fade949ec8bb1c7e","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581752686297380","authorIdStr":"3581752686297380"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/DOCU\">$Docusign(DOCU)$</a>patience","listText":"<a href=\"https://laohu8.com/S/DOCU\">$Docusign(DOCU)$</a>patience","text":"$Docusign(DOCU)$patience","images":[{"img":"https://static.tigerbbs.com/54995e5c1554ec254eaa32ca807c5196","width":"828","height":"1434"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/129189815","isVote":1,"tweetType":1,"viewCount":666,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":181879150,"gmtCreate":1623387053770,"gmtModify":1704202273190,"author":{"id":"3581752686297380","authorId":"3581752686297380","name":"mloh77","avatar":"https://static.tigerbbs.com/01590b23793ed123fade949ec8bb1c7e","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581752686297380","authorIdStr":"3581752686297380"},"themes":[],"htmlText":"Very volatile.","listText":"Very volatile.","text":"Very volatile.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/181879150","repostId":"2142278359","repostType":4,"isVote":1,"tweetType":1,"viewCount":444,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":159136184,"gmtCreate":1624947030748,"gmtModify":1703848599718,"author":{"id":"3581752686297380","authorId":"3581752686297380","name":"mloh77","avatar":"https://static.tigerbbs.com/01590b23793ed123fade949ec8bb1c7e","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581752686297380","authorIdStr":"3581752686297380"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/RRL.AU\">$Regis Resources Ltd(RRL.AU)$</a>Every method shows its undervalued, so why&nbsp;price keeps dropping?","listText":"<a href=\"https://laohu8.com/S/RRL.AU\">$Regis Resources Ltd(RRL.AU)$</a>Every method shows its undervalued, so why&nbsp;price keeps dropping?","text":"$Regis Resources Ltd(RRL.AU)$Every method shows its undervalued, so why price keeps dropping?","images":[{"img":"https://static.tigerbbs.com/f59c64927d47ce5bbdea971b87b4de3d","width":"828","height":"1792"},{"img":"https://static.tigerbbs.com/3d4bc6dcded30256a44196b8500600c8","width":"828","height":"1792"},{"img":"https://static.tigerbbs.com/7140f78193b3385d27328f29726c6aea","width":"828","height":"1792"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/159136184","isVote":1,"tweetType":1,"viewCount":1798,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":3,"langContent":"EN","totalScore":0},{"id":128093601,"gmtCreate":1624494631003,"gmtModify":1703838213098,"author":{"id":"3581752686297380","authorId":"3581752686297380","name":"mloh77","avatar":"https://static.tigerbbs.com/01590b23793ed123fade949ec8bb1c7e","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581752686297380","authorIdStr":"3581752686297380"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/PME.AU\">$Pro Medicus Ltd(PME.AU)$</a>Who else is here because of Investopia?","listText":"<a href=\"https://laohu8.com/S/PME.AU\">$Pro Medicus Ltd(PME.AU)$</a>Who else is here because of Investopia?","text":"$Pro Medicus Ltd(PME.AU)$Who else is here because of Investopia?","images":[{"img":"https://static.tigerbbs.com/a7437c8a39c054aa2a45c36063315d19","width":"828","height":"1434"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/128093601","isVote":1,"tweetType":1,"viewCount":815,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":167260927,"gmtCreate":1624271213869,"gmtModify":1703832068046,"author":{"id":"3581752686297380","authorId":"3581752686297380","name":"mloh77","avatar":"https://static.tigerbbs.com/01590b23793ed123fade949ec8bb1c7e","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581752686297380","authorIdStr":"3581752686297380"},"themes":[],"htmlText":"Noted","listText":"Noted","text":"Noted","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/167260927","repostId":"1184501396","repostType":4,"repost":{"id":"1184501396","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1624267024,"share":"https://ttm.financial/m/news/1184501396?lang=&edition=fundamental","pubTime":"2021-06-21 17:17","market":"us","language":"en","title":"Orphazyme rose more than 6% in premarket trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1184501396","media":"Tiger Newspress","summary":"(June 21) Orphazyme rose more than 6% in premarket trading. \n\nWhat happened\nShares of Orphazyme, a c","content":"<p>(June 21)&nbsp;Orphazyme rose more than 6% in premarket trading.&nbsp;</p>\n<p><img src=\"https://static.tigerbbs.com/a1e2eb27cc68ce74ddd21a64a64634cf\" tg-width=\"719\" tg-height=\"495\" referrerpolicy=\"no-referrer\"></p>\n<p><b>What happened</b></p>\n<p>Shares of&nbsp;<b>Orphazyme</b>, a clinical-stage biopharmaceutical company, got hammered after the Food and Drug Administration (FDA) refused to approve an application for the company's lead candidate. Investors are now uncertain when the biotech could have an approved product to sell, and pushed the stock 44.4% lower as of 12:12 p.m. EDT on last&nbsp;Friday.</p>\n<p><b>So what</b></p>\n<p>The FDA began reviewing an application for Orphazyme's lead candidate arimoclomol last September as a potential treatment for a rare but life-threatening disease called Neimann-Pick Disease Type-C (NPC). Earlier this month, shares of Orphazymeshot upmore than 200% in anticipation of a green light that never came.</p>\n<p>Instead of an approval decision for arimoclomol, the agency asked for more information in the form of a complete response letter (CRL). That came as a shock to heaps of investors who were new to the complex world of drug development and were expecting a massiveshort squeeze.</p>\n<p>Many institutional investors were betting against Orphazyme because its lead candidate failed to achieve the primary endpoint in the pivotal study underpinning the application. Arimoclomol also failed to improve patients' scores on a secondary endpoint specifically requested by the FDA.</p>\n<p><b>Now what</b></p>\n<p>According to Orphazyme, the company needs to further substantiate the validity of the primary endpoint that arimoclomol almost achieved. To satisfy the FDA, the company will most likely have to run a new pivotal study.</p>\n<p>Some shareholders remain hopeful that the European Medicines Agency will be less strict than the FDA. While the FDA's European colleague has been more lenient regarding treatments for rare diseases in the past, arimoclomol probably isn't moving forward until it produces some convincing clinical-trial results.</p>\n<p>Despite lacking a clear path forward, the Denmark-headquartered company still boasts a fairly large market cap in excess of $500 million at recent prices. Irrational expectations could keep it elevated, but this is way too high for anyclinical-stage biotechin Orphazyme's position.</p>\n<p></p>\n<p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Orphazyme rose more than 6% in premarket trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOrphazyme rose more than 6% in premarket trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-06-21 17:17</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(June 21)&nbsp;Orphazyme rose more than 6% in premarket trading.&nbsp;</p>\n<p><img src=\"https://static.tigerbbs.com/a1e2eb27cc68ce74ddd21a64a64634cf\" tg-width=\"719\" tg-height=\"495\" referrerpolicy=\"no-referrer\"></p>\n<p><b>What happened</b></p>\n<p>Shares of&nbsp;<b>Orphazyme</b>, a clinical-stage biopharmaceutical company, got hammered after the Food and Drug Administration (FDA) refused to approve an application for the company's lead candidate. Investors are now uncertain when the biotech could have an approved product to sell, and pushed the stock 44.4% lower as of 12:12 p.m. EDT on last&nbsp;Friday.</p>\n<p><b>So what</b></p>\n<p>The FDA began reviewing an application for Orphazyme's lead candidate arimoclomol last September as a potential treatment for a rare but life-threatening disease called Neimann-Pick Disease Type-C (NPC). Earlier this month, shares of Orphazymeshot upmore than 200% in anticipation of a green light that never came.</p>\n<p>Instead of an approval decision for arimoclomol, the agency asked for more information in the form of a complete response letter (CRL). That came as a shock to heaps of investors who were new to the complex world of drug development and were expecting a massiveshort squeeze.</p>\n<p>Many institutional investors were betting against Orphazyme because its lead candidate failed to achieve the primary endpoint in the pivotal study underpinning the application. Arimoclomol also failed to improve patients' scores on a secondary endpoint specifically requested by the FDA.</p>\n<p><b>Now what</b></p>\n<p>According to Orphazyme, the company needs to further substantiate the validity of the primary endpoint that arimoclomol almost achieved. To satisfy the FDA, the company will most likely have to run a new pivotal study.</p>\n<p>Some shareholders remain hopeful that the European Medicines Agency will be less strict than the FDA. While the FDA's European colleague has been more lenient regarding treatments for rare diseases in the past, arimoclomol probably isn't moving forward until it produces some convincing clinical-trial results.</p>\n<p>Despite lacking a clear path forward, the Denmark-headquartered company still boasts a fairly large market cap in excess of $500 million at recent prices. Irrational expectations could keep it elevated, but this is way too high for anyclinical-stage biotechin Orphazyme's position.</p>\n<p></p>\n<p></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1184501396","content_text":"(June 21) Orphazyme rose more than 6% in premarket trading. \n\nWhat happened\nShares of Orphazyme, a clinical-stage biopharmaceutical company, got hammered after the Food and Drug Administration (FDA) refused to approve an application for the company's lead candidate. Investors are now uncertain when the biotech could have an approved product to sell, and pushed the stock 44.4% lower as of 12:12 p.m. EDT on last Friday.\nSo what\nThe FDA began reviewing an application for Orphazyme's lead candidate arimoclomol last September as a potential treatment for a rare but life-threatening disease called Neimann-Pick Disease Type-C (NPC). Earlier this month, shares of Orphazymeshot upmore than 200% in anticipation of a green light that never came.\nInstead of an approval decision for arimoclomol, the agency asked for more information in the form of a complete response letter (CRL). That came as a shock to heaps of investors who were new to the complex world of drug development and were expecting a massiveshort squeeze.\nMany institutional investors were betting against Orphazyme because its lead candidate failed to achieve the primary endpoint in the pivotal study underpinning the application. Arimoclomol also failed to improve patients' scores on a secondary endpoint specifically requested by the FDA.\nNow what\nAccording to Orphazyme, the company needs to further substantiate the validity of the primary endpoint that arimoclomol almost achieved. To satisfy the FDA, the company will most likely have to run a new pivotal study.\nSome shareholders remain hopeful that the European Medicines Agency will be less strict than the FDA. While the FDA's European colleague has been more lenient regarding treatments for rare diseases in the past, arimoclomol probably isn't moving forward until it produces some convincing clinical-trial results.\nDespite lacking a clear path forward, the Denmark-headquartered company still boasts a fairly large market cap in excess of $500 million at recent prices. Irrational expectations could keep it elevated, but this is way too high for anyclinical-stage biotechin Orphazyme's position.","news_type":1,"symbols_score_info":{"ORPH":0.9}},"isVote":1,"tweetType":1,"viewCount":559,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}